Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

722
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
722
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.1K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.2K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.2K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.1K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

122
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
122
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

502
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
502

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Air Pollution and Cardiovascular Health: Turning Evidence Into Action.

Journal of the American College of Cardiology·2026
Same author

Warming Planet, Aging Population, and Cardiovascular Crisis.

JAMA cardiology·2026
Same author

Artificial intelligence in breaking the learning curve for echocardiography: a secondary analysis of a multicentre trial.

European heart journal. Digital health·2026
Same author

Incorporating Planetary Health Into Clinical Guideline Decisions.

Annals of internal medicine·2026
Same author

Transcatheter Tricuspid Valve Intervention Versus Optimal Medical Therapy in Symptomatic Tricuspid Regurgitation: A Systematic Review and Meta-Analysis of Randomized and Observational Studies.

The American journal of cardiology·2026
Same author

Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients With Type 2 Diabetes and Diabetic Retinopathy.

American journal of ophthalmology·2026

Related Experiment Video

Updated: Dec 6, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.8K

Angiotensin II Administration in Patients With COVID-19 Shock.

Kwadwo Ofosu-Barko1, Yi Liu1, Faisal Alkhatib Tamimi1

  • 1From the Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA.

Critical Pathways in Cardiology
|October 8, 2020
PubMed
Summary

Angiotensin II showed a favorable hemodynamic effect in patients with COVID-19 related shock, reducing the need for norepinephrine equivalent dose. Further research is warranted to evaluate its efficacy in treating this critical condition.

More Related Videos

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

38.7K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K

Related Experiment Videos

Last Updated: Dec 6, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.8K
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

38.7K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.5K

Area of Science:

  • Critical Care Medicine
  • Pharmacology
  • Infectious Diseases

Background:

  • COVID-19 infection can lead to shock, a life-threatening condition.
  • The renin-angiotensin-aldosterone system is implicated in SARS-CoV-2 pathogenesis.
  • Vasopressors are crucial for managing shock, but their optimal use in COVID-19 is under investigation.

Purpose of the Study:

  • To assess the hemodynamic impact of angiotensin II in patients experiencing shock due to COVID-19.
  • To determine if angiotensin II can effectively reduce vasopressor requirements in this patient population.

Main Methods:

  • Retrospective analysis of patients with COVID-19 and shock treated with angiotensin II.
  • Hemodynamic parameters including mean arterial pressure, norepinephrine equivalent dose (NED), and urine output were monitored.
  • Data collected over the initial 6 hours of angiotensin II treatment.

Main Results:

  • Ten patients with COVID-19 related shock received angiotensin II.
  • The average norepinephrine equivalent dose (NED) decreased by 30.4% within 6 hours.
  • Six patients achieved at least a 25% reduction in NED, with two experiencing a >50% reduction; mean arterial pressure remained stable.

Conclusions:

  • Angiotensin II demonstrated a beneficial hemodynamic response in COVID-19 related shock.
  • Two patients exhibited significant and rapid improvement.
  • Further investigation into angiotensin II for COVID-19 shock is recommended due to the virus's interaction with the renin-angiotensin-aldosterone system.